Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps

List view / Grid view

Hans-Joachim Anders

 

Reducing microbial contamination via sterile risk assessment
Reducing microbial contamination via sterile risk assessment
article

Overview of rapid microbiological methods evaluated, validated and implemented for microbiological quality control

The risk for patients through spoiled or otherwise adulterated pharmaceuticals…

19 April 2011 | By Oliver Gordon, Jennifer C. Gray, Hans-Joachim Anders, Alexandra Staerk & Oliver Schlaefli, Novartis Pharma Stein AG and Gunther Neuhaus, University of Freiburg

The risk for patients through spoiled or otherwise adulterated pharmaceuticals has been acknowledged for many centuries and led to the establishment of Good Manufacturing Practice (GMP) and pharmacopoeial guidelines. Besides chemical purity, pharmaceuticals also have to meet microbiological standards, the latter primarily depending on the administration route. Drug products which…

article

Polyphasic approach to microbial identification

The identification of microorganisms from the pharmaceutical production environment has…

28 November 2006 | By Hans-Joachim Anders, Marion Keller, Manfred Berchtold and Werner Hecker, Novartis Pharma Stein AG, Biological and Microbiological Services, Switzerland

The identification of microorganisms from the pharmaceutical production environment has gained an ever greater importance in modern times. Thus the new Aseptic Processing Guide of the FDA recommends the identification of detected isolates from the critical clean room area (grade A or ISO 5) down to the species level and…